Abstract: Pyridoxine-dependent epilepsy (PDE) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine. Recently, the mutation p.Leu455Pro has been identified in the ALDH7A1 gene in Tunisian families with PDE. We investigated two unrelated patients affected with PDE. Diagnosis as having PDE was confirmed by pyridoxine-withdrawal test. To confirm linkage to ALDH7A1 gene, genotyping and direct sequencing of ALDH7A1 gene were performed. Genotyping analysis revealed linkage with ALDH7A1 locus and suggested the segregation of different mutations in these two affected families. Mutation screening revealed the presence of two mutations c.1279G>C (p.Glu427Gln) and c.1292C>T (p.Pro431Leu) in the ALDH7A1 gene. The molecular modeling and bioinformatics studies of these two variations suggest that irregular structures of the mutated ALDH7A1 proteins are likely to cause the functional defect that contributes to the pathology of PDE. On the other hand, our findings indicate an allelic heterogeneity of PDE in Tunisian population.
Introduction
 Pyridoxine dependent epilepsy (PDE) is a disorder of neonates or infants with autosomal recessive inheritance (MIM#266100) characterized by a combination of various seizure types. Affected individuals are unresponsive to standard anticonvulsants but they can be controlled by pharmacological doses of pyridoxine [1, 2] . In 2006, mutations in ALDH7A1 gene have been identified to cause PDE [3] . The ALDH7A1 gene has 53,550 bp, including 4953 bp of coding sequence, and spans 18 exons (GenBank NM_001201377.1). It encodes antiquitin (also known as ALDH7A1, α-AASA or ATQ), an α-aminoadipic-semialdehyde dehydrogenase in the pipecolic acid pathway of lysine catabolism. This enzyme catalyzes the conversion of α-aminoadipic semialdehyde (αAASA) to α-aminoadipic acid. The reaction requires NAD+ as cofactor [4] . Antiquitin deficiency causes epilepsies, because it leads to severe secondary deficiency of pyridoxal 5′-phosphate, which is an essential enzyme cofactor in the metabolism of several amino acids and neurotransmitters [3, 5] .
Up to now, more than 70 ALDH7A1 different pathogenic mutations within the 18 exons of the ALDHA1 gene have been reported in the literature associated with PDE phenotypic spectrum in patients from diverse ethnic backgrounds [6] . The majorities of ALDH7A1 mutations are single-base changes with 38 are missense, 7 are nonsense, and 15 are splice site mutations. Two previous studies on seven Tunisian families affected with PDE, revealed the presence of a common founder missense mutation c.1364T>C (p.Leu455Pro) [7] .
In this study, we have enlarged the mutational spectrum of the ALDH7A1 gene in the Tunisian population, with the identification of two additional gene alterations. We also performed an in silico investigation to predict the potential effect of the identified mutations on structure of the mutated proteins.
Experimental Setup

Patients
In this study we investigated two Tunisian consanguineous families transmitting an autosomal recessive PDE (Fig. 1 ).
The two patients were suspected to be affected with PDE on the basis of seizures resistant to anticonvulsants, good response to pyridoxine and pyridoxine withdrawal test.
Peripheral blood samples were collected from unaffected parents and all families' members after informed consent obtained in accordance with the ethics committee of Hedi Chaker Hospital (Sfax, Tunisia).
DNA Extraction
DNA extraction was performed following standard phenol-chloroform method [8] .
Microsatellite Typing
For the genotypic analysis, we screened the microsatellite marker D5S2059, located approximately 1 megabase upstream of the ALDH7A1 gene. We used the True Allele PCR Premix (Applied Biosystems, Foster City, CA) in the presence of 2.5 pmol of 5-propargylamino-dCTP-6-FAM (Jena Bioscience) for PCR reactions. Fluorescently-labeled alleles were analyzed on an ABI PRISM 3100-Avant automated Genetic Analyser (Applied Biosystems, Foster City, CA). Genotypes were determined using the Gene Mapper software (Applied Biosystems, Foster City, CA).
Mutation Analysis of ALDH7A1 Gene
The 18 exons and flanking intron regions of the ALDH7A1 gene were tested for mutations in the PDE patients by sequence analysis. The coding regions and intron-exon boundaries were amplified using specific primers. PCR products were purified and sequenced as previously described [6] .
The sequence alignment and the pathogenicity prediction
The sequence alignment of the ALDH7A1 gene was performed using the Clustal W program (http://www.ebi.ac.uk/Tools/msa/clustalw2). To predict whether an amino acid substitution affects the ALDH7A1protein function SIFT (http://sift.jcvi.org/) and PolyPhen (http://genetics.bwh.harvard.edu/pph2/) were used.
Molecular Modeling of ALDH7A1 Protein
To investigate the eventual effect of the ALDH7A1 mutations, we modeled and compared the wild type and mutated proteins. Protein crystal structures were taken from (PDB) by 3D-JIGSAW. The models were evaluated on the basis of geometrical and stereo-chemical constraints using: ProSA-Web (https://prosa.services.came.sbg.ac.at/prosa.php) and Verify 3D (http://nihserver.mbi.ucla.edu/Verify_3D/). Deep View/Suiss-PDB viewer 3.7 was used to display and compare models.
Experimental Results
Two Tunisian unrelated consanguineous families including two patients with PDE, were investigated (Fig. 1) . We first screened in the two studied patients the founder mutation c.1364T>C previously described in the Tunisian population. Since this gene alteration was absent in the patients, linkage analysis to the ALDH7A1 gene was performed. Six individuals belonging to the two studied families were genotyped using the informative microsatellite marker D5S2059. Genotyping analysis revealed that in the first family, the 183 bp allele of D5S2059 marker segregates with the disease whereas in the second family, segregation was found with another allele of 191 bp (Fig. 1) .
Result of genotyping analysis suggested the presence of two different mutations in the tested families. So, mutation screening of all ALDH7A1 coding region and intron-exon boundaries was performed and revealed the segregation of the c.1279G>C mutation in first family and the segregation of the c.1292C>T mutation in the second family (Fig. 1) . We found that parents were carriers, whereas the variations c.1279G>C and c.1292 C>T were not found in 100 control alleles.
To predict whether these two mutations (Glu427Gln) and (Pro431Leu) could potentially affect the protein function, Polyphen-2 and SIFT were used. As a result, we found that these amino acids are highly conserved and their substitutions are predicted to be "damaging" (data not shown).
The Glu427Gln and Pro431Leu mutations were also modeled using Deep View/Suiss-PDB viewer 3.7 software. The comparison between the normal and the mutant structures showed that in both situations the root mean squares (RMS) were very significant (19.11 Å and 18.61 Å, respectively). Interestingly, we noticed also that these two substitutions add one hydrogen bond between (Thr428-Ala430) (Fig. 2) . These findings suggest that the overall architectures of the mutant proteins were different to that of wild-type protein.
Discussion
We report two Tunisian consanguineous families affected with PDE. The affected patients had an early diagnosis of PDE and received appropriate pyridoxine therapy. In 2000, Cormier et al. localized a PDE disease causing gene to chromosome 5 locus q31.2 [9] . In 2006, Mills et al. identified the ALDH7A1gene as responsible for PDE since they detected mutations in affected PDE persons [3] . So far, several mutations in the antiquitin (ALDH7A1) gene have been described [6] . In the absence of the unique mutation c.1364T>C, previously reported in the Tunisian population [6] , genotyping analysis showed that both patients are homozygous for two different alleles of the closest marker to ALDH7A1 gene, D5S2059. Sequencing and mutation analysis confirmed the presence of the two different mutations, c.1279G>C and c.1292 C>T. The first mutation, c.1279G>C has been reported to be prevalent in Caucasian patients [5] , it substitutes the Glutamic amino acid at position 427 to a Glutamin residu. Whereas, the c.1292C>T transition was reported once, in a heterozygous form in trans with an intronic splicing mutation [10] . It is a missense mutation which substitutes a Proline at position 431 to a Leucine residu. Both Sift and Polyphen predict that these mutations showed to have a damaging effect on the protein function. Interestingly, modeling results showed that these two different mutations are predicted to have the same impact. In fact, both Glu427Gln and Pro431Leu mutations induce the addition of one hydrogen bond between amino acids Thr428 and Ala430. This extra-bond makes the surrounding region tighter, which might affect the shape and the conformation of the corresponding domain. Previous studies suggested that these two amino acids are located in the NAD+ cofactor binding site [11] . The interaction between this site and the NAD+ cofactor is crucial to make the substrate site accessible and allows formation of the ternary enzyme-cofactor (NAD+)-substrate (αAASA)
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Conclusions
Our result takes the number of published disease causing mutations in ALDH7A1 gene in the Tunisian population to three and confirmed the mutational heterogeneity of PDE in Tunisia. In addition, our findings suggest that the Glu427Gln and Pro431Leu mutations might indirectly affect the ALDH7A1 catalytic function by reducing or inhibiting the substrate (αAASA) -enzyme (ALDH7A1) interaction.
